We are live on
!
Find out more
MAA
Mraz Amerine & Associates Portfolio holdings
AUM
$697M
1-Year Est. Return
19.37%
This Fund
S&P 500
This Quarter
Est. Return
+1.06%
1 Year Est. Return
+19.37%
3 Year Est. Return
+69.82%
5 Year Est. Return
+110.04%
10 Year Est. Return
+286.7%
AUM
$623M
AUM Growth
+$41.5M
(+7.1%)
Cap. Flow
+$24.9M
Cap. Flow
% of AUM
3.99%
Top 10 Holdings %
Top 10 Hldgs %
58.07%
Holding
198
New
28
Increased
69
Reduced
64
Closed
7
Top Buys
| 1 |
WisdomTree Floating Rate Treasury Fund
USFR
|
+$3.4M |
| 2 |
Janus Henderson AAA CLO ETF
JAAA
|
+$2.96M |
| 3 |
Carlisle Companies
CSL
|
+$1.6M |
| 4 |
Jefferies Financial Group
JEF
|
+$1.43M |
| 5 |
PGIM AAA CLO ETF
PAAA
|
+$1.02M |
Top Sells
| 1 |
ESGR
Enstar Group
ESGR
|
+$5.89M |
| 2 |
BPMC
Blueprint Medicines
BPMC
|
+$478K |
| 3 |
Hallador Energy
HNRG
|
+$395K |
| 4 |
Dimensional US Large Cap Value ETF
DFLV
|
+$270K |
| 5 |
Entergy
ETR
|
+$249K |
Sector Composition
| 1 | Financials | 60.28% |
| 2 | Energy | 10.28% |
| 3 | Industrials | 3.43% |
| 4 | Technology | 2.97% |
| 5 | Materials | 1.87% |
Similar funds
GUB
FCM
AWC
SCM
AIA
CA
KLI
JA
Mraz Amerine & Associates's Q2 2025 Portfolio in Review
As of Q2 2025, Mraz Amerine & Associates held 198 positions worth $623M, up 7.1% from $582M the previous quarter. Its ten largest holdings account for 58% of the portfolio.
Mraz Amerine & Associates deployed $24.9M of net new capital in Q2 2025, opening 28 new positions and adding to 69 existing holdings. Its largest new stake was Carlisle Companies: 4,315 shares worth $1.61M.
By sector, the portfolio is most concentrated in Financials at 60% of assets, down from 62% a quarter earlier, followed by Energy and Industrials.
On the sell side, the largest reduction was Enstar Group, an estimated $5.89M trimmed.
- Mraz Amerine & Associates's largest Q2 2025 buy was Carlisle Companies: 4,315 shares worth $1.61M.
- Mraz Amerine & Associates added most to WisdomTree Floating Rate Treasury Fund in Q2 2025, an estimated $3.4M increase.
- Mraz Amerine & Associates's biggest Q2 2025 reduction was Enstar Group, cutting an estimated $5.89M.
- Mraz Amerine & Associates fully exited Blueprint Medicines in Q2 2025, selling an estimated $478K.
- Mraz Amerine & Associates's ten largest holdings make up 58% of its $623M portfolio in Q2 2025.
- Mraz Amerine & Associates opened 28 new positions and closed 7 in Q2 2025.
- Mraz Amerine & Associates's portfolio value rose 7.1% quarter-over-quarter to $623M.
Based on Mraz Amerine & Associates's 13F filing for Q2 2025, filed 23 Jul 2025.